Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekt av 10 mg Xanamem på demens på grunn av Alzheimers sykdom (XanaMIA)

19. oktober 2026 oppdatert av: Actinogen Medical

En fase 2b, dobbeltblind, placebokontrollert, parallellgruppe, 36-ukers, 2-arms studie for å vurdere sikkerheten, toleransen og effekten av Xanamem® 10 mg daglig hos pasienter med mild eller moderat demens på grunn av Alzheimers sykdom

Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).

This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Studietype

Intervensjonell

Registrering (Faktiske)

247

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New South Wales
      • Darlinghurst, New South Wales, Australia
        • ACW Investigative Site 106
      • Erina, New South Wales, Australia
        • ACW Investigative Site 103
      • Kogarah, New South Wales, Australia
        • ACW Investigative Site 102
      • Macquarie Park, New South Wales, Australia
        • ACW Investigative Site 107
      • Newcastle, New South Wales, Australia
        • ACW Investigative Site 111
    • Queensland
      • Birtinya, Queensland, Australia
        • ACW Investigative Site 113
      • Chermside, Queensland, Australia
        • ACW Investigative Site 105
    • South Australia
      • Bedford Park, South Australia, Australia
        • ACW Investigative Site 114
      • Woodville South, South Australia, Australia
        • ACW Investigative Site 110
    • Victoria
      • Carlton, Victoria, Australia
        • ACW Investigative Site 115
      • Ivanhoe, Victoria, Australia
        • ACW Investigative Site 101
      • Malvern, Victoria, Australia
        • ACW Investigative Site 108
      • Parkville, Victoria, Australia
        • ACW Investigative Site 112
    • Western Australia
      • Nedlands, Western Australia, Australia
        • ACW Investigative Site 104
      • West Perth, Western Australia, Australia
        • ACW Investigative Site 109
    • California
      • Carlsbad, California, Forente stater, 92011
        • ACW Investigative Site 218
      • Sherman Oaks, California, Forente stater, 91403
        • ACW Investigative Site 209
    • Colorado
      • Denver, Colorado, Forente stater, 80218
        • ACW Investigative Site 211
      • Englewood, Colorado, Forente stater, 80113
        • ACW Investigative Site 208
    • Florida
      • Delray Beach, Florida, Forente stater, 33445
        • ACW Investigative Site 203
      • Miami, Florida, Forente stater, 33176
        • ACW Investigative site 201
      • New Port Richey, Florida, Forente stater, 34652
        • ACW Investigative site 202
      • Orlando, Florida, Forente stater, 32803
        • ACW Investigative site 204
      • The Villages, Florida, Forente stater, 32162
        • ACW Investigative site 205
    • Georgia
      • Decatur, Georgia, Forente stater, 30030
        • ACW Investigative Site 207
    • New Jersey
      • Marlton, New Jersey, Forente stater, 08053
        • ACW Investigative Site 206
    • New York
      • Albany, New York, Forente stater, 12208
        • ACW Investigative Site 214
      • Staten Island, New York, Forente stater, 10314
        • ACW Investigative Site 219
    • Ohio
      • Dayton, Ohio, Forente stater, 45459
        • ACW Investigative Site 210
      • Independence, Ohio, Forente stater, 44131
        • ACW Investigative Site 217
    • Oregon
      • Portland, Oregon, Forente stater, 97225
        • ACW Investigative Site 212
    • Rhode Island
      • East Providence, Rhode Island, Forente stater, 02914
        • ACW Investigative Site 216
    • Texas
      • Austin, Texas, Forente stater, 78757
        • ACW Investigative Site 220
    • Washington
      • Bellevue, Washington, Forente stater, 98007
        • ACW Investigative Site 215

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

50 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female aged 50 years or older, inclusive at the time of Screening.

  • Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:

    1. Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
    2. Mini-mental state examination (MMSE) score of 18 to 26
    3. Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
    4. Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
  • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.

  • Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.

  • Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.

  • Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.

  • Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.

Exclusion Criteria:

  • Use of anti-amyloid or anti-tau antibody within 6 months.
  • Diagnosis of a non-AD dementia including traumatic brain injury.
  • Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
  • Participation in another clinical trial of a drug or device
  • Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
  • Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
  • Clinical diagnosis of Type I or Type II diabetes requiring insulin.
  • Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C.
  • Participants with a history of clinically significant drug abuse or addiction in the past 2 years
  • Evidence or history of alcohol abuse

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: 10 mg Xanamem

10 mg Xanamem tablet, to be administered orally once every morning with or without food

Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.

Andre navn:
  • UE2343
Placebo komparator: Placebo

Placebo tablet, to be administered orally once every morning with or without food

Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.

Eksperimentell: Open label phase

Participants enrolled in the open-label phase after the main trial will receive 10 mg Xanamem, to be administered orally once every morning with or without food

Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.

Andre navn:
  • UE2343

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Effects of 10 mg Xanamem on integrated cognitive and functional abilities
Tidsramme: 36 weeks

Change from Baseline to end of treatment (EOT) in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB). The CDR-SB is calculated as an average score, with lower scores indicating improvement.

36 weeks
Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]
Tidsramme: 36 weeks

Incidence and severity of TEAEs

36 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Global Program Lead, Actinogen Medical Ltd

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. april 2024

Primær fullføring (Faktiske)

22. september 2026

Studiet fullført (Antatt)

1. februar 2028

Datoer for studieregistrering

Først innsendt

23. oktober 2023

Først innsendt som oppfylte QC-kriteriene

5. november 2023

Først lagt ut (Faktiske)

9. november 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

19. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere